XM no presta servicios a los residentes de Estados Unidos de América.
C
C

Cigna


Noticias

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year By Patrick Wingrove Aug 26 (Reuters) - Cigna CI.N said on Monday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead.
A
C
P
T

U.S. Agree Realty, Global Payments, Snowflake

U.S. RESEARCH ROUNDUP- Agree Realty, Global Payments, Snowflake Aug 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agree Realty, Global Payments and Snowflake on Wednesday. HIGHLIGHTS * Agree Realty Corp ADC.N : Raymond James raises target price to $81 from $70 * Coinbase Global Inc COIN.O : Jefferies cuts target price to $220 from $245 * Global Payments Inc GPN.N : Jefferies raises target price to $130 from $120
A
B
C
C
P
V
E
G
M
K
L

Venture capital firms making bets on maternal health

FOCUS-Venture capital firms making bets on maternal health By Amina Niasse NEW YORK, Aug 19 (Reuters) - After working as a doula for 10 years, Kortny Feutardo took her first Maryland Medicaid patient in January, providing the new mom with care coordination and counseling. Feutardo is one of many providers benefiting from growing investment in the maternal and neonatal health sector .
C

The Cigna Group Foundation Launches Grant Program To Improve Veteran Mental Health

BRIEF-The Cigna Group Foundation Launches Grant Program To Improve Veteran Mental Health Aug 12 (Reuters) - Cigna Group CI.N : THE CIGNA GROUP FOUNDATION LAUNCHES GRANT PROGRAM TO IMPROVE VETERAN MENTAL HEALTH Source text for Eikon: ID:nPn2HqD7a Further company coverage: CI.N ( Reuters.Briefs@thomsonreuters.com )
C

U.S. Booking Holdings, Doordash, Vertex Pharmaceuticals

U.S. RESEARCH ROUNDUP- Booking Holdings, Doordash, Vertex Pharmaceuticals Aug 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Booking Holdings, Doordash and Vertex Pharmaceuticals, on Monday. HIGHLIGHTS * Academy Sports and Outdoors Inc ASO.O : JP Morgan cuts to neutral from overweight * Booking Holdings Inc BKNG.O : Jefferies cuts target price to $4350 from $4650 * Doordash DASH.O : D.A.
A
B
C
C
C
C
E
V
E
A
B
C
C
C
C

Cigna falls after unchanged annual forecast despite profit beat

BUZZ-Cigna falls after unchanged annual forecast despite profit beat ** Shares of health insurer Cigna fall 4.8% to $331.80 ** Set for biggest one-day pct. fall since Nov. 2023 ** Co maintains its annual profit forecast after Q2 profit beat ** The lack of forecast raise despite the beat will be likely viewed as a modest disappointment - Leerink Partners ** Brokerage expects investors to keenly focus on determining if this resulted from more prudent posturing or a synthetic guide-down of the seco
C

Health insurer Cigna's cautious annual forecast spooks investors, shares fall

UPDATE 2-Health insurer Cigna's cautious annual forecast spooks investors, shares fall New throughout, adds details, background, analyst comments, updates share price By Amina Niasse and Sriparna Roy Aug 1 (Reuters) - Cigna CI.N took a cautious stance on its full-year profit outlook on Thursday despite reporting lower-than-feared medical costs in the second quarter and beating Wall Street's profit estimates, and the health insurer's shares fell more than 4%.
C

Fed nods to cut, chips rebound, BoE up next

MORNING BID AMERICAS-Fed nods to cut, chips rebound, BoE up next A look at the day ahead in U.S. and global markets from Mike Dolan The Federal Reserve left Wall Street with little doubt about a first U.S. interest rate cut in seven weeks' time, but multiple cross-currents from the earnings season , Japan and China, and domestic politics all make for a noisy start to August.
A
A
A
B
C
G
I
N
R
U
X
M
J
U
U
U
F
E
W
A
M

Cigna beats profit estimates on lower-than-expected costs, pharmacy benefit boost

Cigna beats profit estimates on lower-than-expected costs, pharmacy benefit boost Aug 1 (Reuters) - Cigna CI.N reported a second-quarter profit on Thursday that beat Wall Street estimates, helped by lower-than-expected medical costs and strength in its pharmacy benefit management unit. The industry has been contending with elevated medical costs since late last year, as older adults catch up on delayed procedures, and lower-than-expected payments from the government for managing healthcare for p
C

What to Watch in the Day Ahead - Thursday, August 1

What to Watch in the Day Ahead - Thursday, August 1 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Apple is expected to report a rise in third-quarter revenue, helped by higher iPad sales from new launches and strength in its services business.
A
A
B
C
I
K
V
M
B

Humana slides on higher medical care use; other health insurers fall

BUZZ-Humana slides on higher medical care use; other health insurers fall Updates ** Shares of health insurer Humana HUM.N fall 6 .4% to $378 .63 , their biggest one-day loss pct since April ** Co reports higher-than-anticipated inpatient admissions - hospitalizations that require overnight stay - in second half of Q2 ** We continue to assess the durability of the higher admissions - HUM ** Shares of other health insurers also fall ** Shares of UnitedHealth UNH.N dip 1.2%, Elevance ELV.N down 1
C

Cigna Group <CI.N> expected to post earnings of $6.41 a share - Earnings Preview

Cigna Group expected to post earnings of $6.41 a share - Earnings Preview Cigna Group CI.N , CI is expected to show a rise in quarterly revenue when it reports results on August 1 for the period ending June 30 2024 The Bloomfield Connecticut-based company is expected to report a 20.0% increase in revenue to $58.329 billion from $48.62 billion a year ago, according to the mean estimate from 16 analysts, based on LSEG data.
C

AbbVie lifts 2024 profit forecast, shares hit record high

UPDATE 2-AbbVie lifts 2024 profit forecast, shares hit record high Adds information from investor call throughout, updates shares in paragraph 3 By Leroy Leo and Patrick Wingrove July 25 (Reuters) - AbbVie ABBV.N increased its profit forecast for 2024 on Thursday after reporting strong sales of immunology drugs and quarterly results that exceeded Wall Street expectations, sending its shares to a record high.
C

AbbVie lifts annual profit forecast on strong immunology drug sales

AbbVie lifts annual profit forecast on strong immunology drug sales July 25 (Reuters) - AbbVie ABBV.N raised its annual profit forecast on Thursday as strong sales of its key immunology drugs, including Humira, helped it beat Wall Street expectations for the second quarter. Sales of Humira, once the world's top-selling drug, have been declining since its close copies, or biosimilars, hit the U.S.
C

Cigna Group Declares Quarterly Dividend

BRIEF-Cigna Group Declares Quarterly Dividend July 24 (Reuters) - Cigna Group CI.N : THE CIGNA GROUP DECLARES QUARTERLY DIVIDEND CIGNA GROUP - DECLARES QUARTERLY DIVIDEND OF $1.40 PER SHARE Source text for Eikon: ID:nPn2gnfkja Further company coverage: CI.N
C

US drug industry middlemen defend business model amid accusations of raising patient costs

UPDATE 1-US drug industry middlemen defend business model amid accusations of raising patient costs Recasts with details from hearing in paragraphs 1, 4-9, 10 By Amina Niasse and Bhanvi Satija July 23 (Reuters) - U.S. pharmaceutical industry middlemen defended their role in the healthcare system during a Congressional hearing on Tuesday after committee members accused them of pushing patients toward expensive treatments even when lower-cost options are available.
C

Drug middlemen push for pricier medicines, US House committee report finds

Drug middlemen push for pricier medicines, US House committee report finds July 23 (Reuters) - U.S. pharmacy benefit managers push patients towards more expensive treatments even when lower-cost options are available, according to a report by the House Committee on Oversight and Accountability. The committee said it has found evidence that pharmacy benefit managers (PBMs) force drugmakers to pay rebates for placing their branded drugs in a favorable position on a formulary or the list of medicat
C

The Cigna Group Foundation Launches Its Health Equity Impact Fund

BRIEF-The Cigna Group Foundation Launches Its Health Equity Impact Fund July 22 (Reuters) - Cigna Group CI.N : THE CIGNA GROUP FOUNDATION LAUNCHES ITS HEALTH EQUITY IMPACT FUND Source text for Eikon: ID:nPn9DcH8ta Further company coverage: CI.N
C

With no big deal safe, investment bankers move to safeguard fees

ANALYSIS-With no big deal safe, investment bankers move to safeguard fees Bankers push for fees on deals that regulators thwart Top banks seek up to 25% of breakup fees Fairness opinion fees rise to 20-25% of success fees By Anirban Sen NEW YORK, July 22 (Reuters) - Investment bankers are changing how they ask to be paid in a bid to preserve and boost fee revenue they generate from advising companies on mergers and acquisitions, as more big deals face challenges by regulators.
B
C
C
G
J
J
U
F

Vermont latest state to sue PBMs for allegedly driving up drug prices

Vermont latest state to sue PBMs for allegedly driving up drug prices By Brendan Pierson July 17 (Reuters) - Vermont's attorney general on Wednesday sued two of the largest U.S. pharmacy benefit managers, accusing them of driving up prescription drug prices for patients in order to enrich themselves, joining other states that have brought similar claims against the drug industry middlemen.
C



Condiciones

Activos populares

Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.

Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.

Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.

Advertencia de riesgo: Su capital está en riesgo. Los productos apalancados pueden no ser adecuados para todos. Por favor, tenga en cuenta nuestra Declaración de riesgos.